Heska (NASDAQ:HSKA – Get Rating) had its price objective decreased by JPMorgan Chase & Co. from $175.00 to $150.00 in a report released on Monday, The Fly reports. JPMorgan Chase & Co. currently has an overweight rating on the medical research company's stock.

HSKA has been the topic of several other reports. Piper Sandler lifted their price target on shares of Heska to $170.00 in a research note on Monday, August 22nd. StockNews.com began coverage on shares of Heska in a research note on Wednesday, October 12th. They issued a hold rating on the stock. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $159.00.

Heska Trading Down 3.0 %

Shares of NASDAQ:HSKA opened at $68.76 on Monday. Heska has a 12 month low of $67.65 and a 12 month high of $252.70. The company has a quick ratio of 5.50, a current ratio of 6.92 and a debt-to-equity ratio of 0.24. The company's fifty day simple moving average is $83.60 and its 200 day simple moving average is $95.44. The firm has a market cap of $743.91 million, a price-to-earnings ratio of -39.98 and a beta of 1.51.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HSKA. Manning & Napier Group LLC increased its stake in shares of Heska by 164.8% during the 1st quarter. Manning & Napier Group LLC now owns 181,566 shares of the medical research company's stock worth $25,105,000 after purchasing an additional 112,997 shares during the last quarter. FMR LLC increased its stake in shares of Heska by 47.3% during the 2nd quarter. FMR LLC now owns 338,042 shares of the medical research company's stock worth $31,948,000 after purchasing an additional 108,574 shares during the last quarter. Monarch Partners Asset Management LLC increased its stake in shares of Heska by 393.9% during the 2nd quarter. Monarch Partners Asset Management LLC now owns 55,337 shares of the medical research company's stock worth $5,230,000 after purchasing an additional 44,132 shares during the last quarter. Sio Capital Management LLC acquired a new position in shares of Heska during the 2nd quarter worth about $3,739,000. Finally, Sei Investments Co. acquired a new position in shares of Heska during the 2nd quarter worth about $3,599,000. 97.39% of the stock is currently owned by institutional investors and hedge funds.

Heska Company Profile

(Get Rating)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers.

Recommended Stories

• Get a free copy of the StockNews.com research report on Heska (HSKA)
• Can Molina Healthcare Sustain Its Market-Beating Rally?
• Cardinal Health Clears Base, But Can It Maintain Uptrend?
• 3 'Luxury' Brands Designed to Beat Inflation
• Is it Time to Take a Ride with Winnebago Stock?
• LVMH's Diversified Luxury Brand Portfolio is Recession Armor

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.